CRISPR Therapeutics (NASDAQ:CRSP) Earns “Market Outperform” Rating from Citizens Jmp

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “market outperform” rating reissued by stock analysts at Citizens Jmp in a note issued to investors on Tuesday,Benzinga reports. They presently have a $80.00 price target on the stock. Citizens Jmp’s price target suggests a potential upside of 40.15% from the company’s current price.

A number of other research firms also recently weighed in on CRSP. Morgan Stanley set a $60.00 target price on CRISPR Therapeutics and gave the stock an “equal weight” rating in a report on Thursday, June 11th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $68.06.

CRISPR Therapeutics Stock Down 4.1%

Shares of CRISPR Therapeutics stock opened at $57.08 on Tuesday. The company’s 50 day moving average price is $53.14 and its 200-day moving average price is $52.43. CRISPR Therapeutics has a 52-week low of $44.12 and a 52-week high of $78.48. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The stock has a market capitalization of $5.52 billion, a price-to-earnings ratio of -11.99 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The business had revenue of $10.18 million during the quarter. Equities research analysts forecast that CRISPR Therapeutics will post -4.47 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,786 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the transaction, the insider owned 19,357 shares in the company, valued at $1,076,636.34. This represents a 16.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CRSP. Versant Capital Management Inc increased its holdings in CRISPR Therapeutics by 175.1% in the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares in the last quarter. Mcguire Capital Advisors Inc. bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $25,000. Ramirez Asset Management Inc. purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $26,000. Rothschild Investment LLC grew its position in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares in the last quarter. Finally, Oakworth Capital Inc. purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $34,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.